Orforglipron Research Guide

Full name: Orforglipron (Oral Non-Peptide GLP-1 Agonist)

A first-in-class oral non-peptide GLP-1 receptor agonist with high oral bioavailability, potentially democratizing GLP-1 therapy without injections.

How Orforglipron Works

Small molecule agonist of GLP-1 receptors that mimics native GLP-1 binding without requiring peptide structure. Achieves full receptor activation with standard oral bioavailability.

Dosing Protocol

• Typical dose: 12-45 mg
• Frequency: Once daily
• Duration: Ongoing
• Route: Oral

Reported Benefits

• Oral administration (no injection)
• No fasting requirement
• Significant weight loss (8-14%)
• Small molecule stability
• Lower manufacturing cost potential

Potential Side Effects

• Nausea (dose-dependent)
• Vomiting
• Diarrhea
• Decreased appetite
• Dyspepsia

Research Citations

1. Phase 2 trial of orforglipron for obesity (2023) - Orforglipron 45mg produced 14.7% weight loss at 36 weeks with manageable GI side effects.
2. Oral non-peptide GLP-1 agonist pharmacokinetics (2023) - Consistent absorption without food restrictions, with 25-60 hour half-life supporting daily dosing.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile

View full Orforglipron profile with 3D molecule viewer →